The Searle Company Limited (SEARL) Corporate Briefing Session: Company highlights strong FY2026 financial performance.
The Searle Company Limited (SEARL)
Corporate Briefing Session - FY 2026
The Searle Company Limited conducted its Corporate Briefing Session for FY 2026, highlighting robust financial recovery and a diversified business platform across the IBL Group.
Key Highlights
- Strong Revenue Growth: Standalone Sales reached PKR 31.64bn in FY 2026, a 28% increase YoY.
- Profitability Turnaround: Standalone Profit After Tax (PAT) improved significantly to PKR 4.00bn compared to PKR 434mn in FY 2025.
- Market Leadership: Fourth largest pharmaceutical company in Pakistan by units sold; over 500,000 daily prescriptions.
- Diversified Footprint: Operates in 16 therapeutic areas with 6 state-of-the-art manufacturing plants.
- Product Pipeline: Significant focus on new launches across pharmaceuticals, nutraceuticals, and medical devices.
Strategic Outlook
Management emphasized brand leadership in key therapeutic areas like Cardiovascular, Gynae, and Cough, with a focus on margin expansion and financial health improvement.
Disclaimer: This summary is based on the provided corporate briefing presentation. No new dividend or corporate entitlement was declared in this filing.